PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 13, 2021New England Journal of Medicine647 citationsOpen Access

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

View Full Paper
AWAaron B. WaxmanRRRicardo Restrepo‐JaramilloTTThenappan Thenappan

Key Points

  • To evaluate the effects of inhaled treprostinil on exercise capacity in patients with pulmonary hypertension due to interstitial lung disease.
  • Randomized comparison of inhaled treprostinil versus placebo
  • Primary outcome assessed using the 6-minute walk test
  • ClinicalTrials.gov NCT02630316
  • Inhaled treprostinil significantly improved exercise capacity compared to placebo, as measured by the 6-minute walk test.

Abstract

In patients with pulmonary hypertension due to interstitial lung disease, inhaled treprostinil improved exercise capacity from baseline, assessed with the use of a 6-minute walk test, as compared with placebo. (Funded by United Therapeutics; INCREASE ClinicalTrials.gov number, NCT02630316.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Waxman et al. (2021) studied this question.

synapsesocial.com/papers/69d5720b75589c71d767e420https://doi.org/10.1056/nejmoa2008470
Ask AI
Helpful
Bookmark
Share
View Full Paper